NCT02510300
A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
Associated Conditions
Infectious DiseaseSponsor
Gilead Sciences
The purpose of this study is to continue to follow the response that the body has after participating in a Gilead-sponsored HCV treatment study.
This study is currently enrolling.